Untitled

Biotechnology R&D InfrastructureDAEJEON-KRIBB-FHCRCResearch Cooperation CenterRESEARCHERSHyang-Sook Yoo yoohyang@kribb.re.krCancer genomicsCell cycle and signaling, yeast genetics and geneexpressionJeong-Heon Ko jhko@kribb.re.krDiscovery of cancer biomarkers that show changes both inquantity and quality, with highly positive prediction values.Functional studies that relate the candidate biomarkerproteins to the biology of a cancerEun Wie Cho ewcho@kribb.re.krDiscovery of auto-antibody-based biomarkers that showchanges in the serum of cancer patientsYong-Sam Kim omsys1@kribb.re.krDiscovery of biomarkers that show changes in terms ofboth quantity (amount of protein in serum level) and quality(aberrant glycosylation), with highly positive predictionvaluesDevelopment of a biomarker validation method andvalidation of candidate cancer biomarkersMechanistic study of cancer progression focused on glycooncoproteinsRESEARCH AREASDiscovery of biomarkers that show changes both inquantity and quality, with highly positive prediction values ingastric, liver, colon and lung cancersFunctional studies that relate candidate biomarkers to thebiology of a cancerThe role of glycolipid in the apoptotic death of mammaliancellsDiscovery of auto-antibodies produced during theprogression of a cancer as cancer biomarkersIdentification of drug targets for use in the treatment ofcancer patientsDirector Hyang-Sook YooT + 82-42-860-4170F + 82-42-879-8119E yoohyang@kribb.re.krACHIEVEMENTSDiscovery and validation of candidate biomarkers for liver cancerThe multi-lectin approach was employed to mine liver cancer-specific serologicalGlycoproteins; 8 proteins were found to be identified only from the sera of HCC patients.The list of candidate HCC biomarkers was patented and will be validated for the narrowingdown of good biomarkers. These candidate biomarkers are being validated usinga DNAtagged antibody-based method.Comparative quantitation of aberrant glycoforms by lectin-based glycoproteinenrichment coupled with multiple-reaction monitoring mass spectrometryLectin enrichment-coupled multiple-reaction monitoring (MRM) mass spectrometry wasemployed to quantitatively monitor the variations of aberrant glycoforms produced underpathological states. For this, dramatic variations in abundance of the aberrantglycoforms of TIMP-1 and PTPk due to overexpressed GnT-V was confirmed quantitativelyby comparative MRM analysis of lectin-enriched samples, allowing comparativelyquantitation of a protein of interest and its aberrant glycoform. This will be useful forstudying pathological mechanisms of cancer and verifying biomarker candidates.Identification of an anti-fatty acid synthase auto-antibody in the HCC mouse model andits application to the diagnosis of HCCWe reported the anti-fatty acid synthase (FASN) auto-antibody in hepatocellularcarcinoma (HCC) using the HCC mouse model and suggested a novel method for thedetection of anti-FASN auto-antibody in patient sera, which is very effective for thediagnosis of HCC.SELECTED PUBLICATIONSYong-Sam Kim (Co-first) Anal Chem. 82(11):4441-7.Comparative quantitation of aberrant glycoforms by lectin-based glycoprotein enrichmentcoupled with multiple-reaction monitoring mass spectrometryEun Wie Cho (Co-corresponding) Biochem Biophys Res Commun. 400(1):100-5.SM22α-induced activation of p16 INK4a /retinoblastoma pathway promotes cellularsenescence caused by a subclinical dose of °V-radiation and doxorubicin in HepG2 cellsEun Wie Cho (Corresponding) Int J Oncol. 36(6):1453-9.Identification of autoantibody against fatty acid synthase in hepatocellular carcinomamouse model and its application to diagnosis of HCCHyang-Sook Yoo (Co-first) Nat Biotechnol. 28(6):617-23.Analysis of a genome-wide set of gene deletions in the fission yeast SchizosaccharomycespombeOur goal is to discover cancer biomarkers of high sensitivity and specificity that are useful for diagnosing and predictingcancers at the earliest possible stage and for monitoring the effects of drugs. In collaboration with the teams from theInternational Cancer Biomarker Consortium led by Dr. Lee Hartwell of the Fred Hutchinson Cancer Research Center, wefocus on identifying biomarkers for the early detection of liver, stomach, colon and other cancers, which will help to treatcancer patients more effectively and efficiently, and ultimately raise the survival rate of cancer patients.96 KRIBB Annual Report 2010KRIBB Annual Report 2010 97